Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Over Expression in Transgenic Mice Suppresses Intestinal Neoplasia

Gastroenterology

Volumn 131, Issue 5, 2006, Pages 1553-1560

  Baek, Seung Joon ^a   Okazaki, Ryuji ^b   Lee, Seong Ho ^a   Martinez, Jeanelle ^b   Kim, Jong Sik ^b   Yamaguchi, Kiyoshi ^a   Mishina, Yuji ^b   Martin, David W ^c   Shoieb, Ahmed ^a   Mcentee, Michael F ^a   Eling, Thomas E ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; BETA ACTIN; CARCINOGEN; NONSTEROIDAL ANTIINFLAMMATORY DRUG ACTIVATED GENE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; COLORECTAL CARCINOMA; GENE INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE POLYP; INTESTINE TUMOR; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 33750736082     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.09.015     Document Type: Article

References (49)

1. Baek S.J., and Eling T.E. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 45 (2006) 1-16
2. Bootcov M.R., Bauskin A.R., Valenzuela S.M., Moore A.G., Bansal M., He X.Y., Zhang H.P., Donnellan M., Mahler S., Pryor K., Walsh B.J., Nicholson R.C., Fairlie W.D., Por S.B., Robbins J.M., and Breit S.N. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci U S A 94 (1997) 11514-11519
3. Bottner M., Laaff M., Schechinger B., Rappold G., Unsicker K., and Suter-Crazzolara C. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 237 (1999) 105-111
4. Hromas R., Hufford M., Sutton J., Xu D., Li Y., and Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1354 (1997) 40-44
5. Paralkar V.M., Vail A.L., Grasser W.A., Brown T.A., Xu H., Vukicevic S., Ke H.Z., Qi H., Owen T.A., and Thompson D.D. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem 273 (1998) 13760-13767
6. Tan M., Wang Y., Guan K., and Sun Y. PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway. Proc Natl Acad Sci U S A 97 (2000) 109-114
7. Baek S.J., Wilson L.C., Lee C.H., and Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301 (2002) 1126-1131
8. Baek S.J., and Eling T.E. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 45 (2006) 1-16
9. Baek S.J., Kim J.S., Jackson F.R., Eling T.E., McEntee M.F., and Lee S.H. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 25 (2004) 2425-2432
10. Baek S.J., Wilson L.C., and Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23 (2002) 425-432
11. Bottone Jr. F.G., Baek S.J., Nixon J.B., and Eling T.E. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 132 (2002) 773-778
12. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., and Baek S.J. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 328 (2005) 63-69
13. Wilson L.C., Baek S.J., Call A., and Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 105 (2003) 747-753
14. Yamaguchi K., Liggett J.L., Kim N.C., and Baek S.J. Anti-proliferative effect of horehound leaf and wild cherry bark extracts on human colorectal cancer cells. Oncol Rep 15 (2006) 275-281
15. Baek S.J., Wilson L.C., Hsi L.C., and Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 278 (2003) 5845-5853
16. Chintharlapalli S., Papineni S., Baek S.J., Liu S., and Safe S. 1,1-Bis(3′-indolyl)-1-(p-substitutedphenyl) methanes are peroxisome proliferator-activated receptor (γ) agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 68 (2005) 1782-1792
17. Yamaguchi K., Lee S.H., Eling T.E., and Baek S.J. A novel peroxisome proliferator-activated receptor γ ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 5 (2006) 1352-1361
18. Monks A., Harris E., Hose C., Connelly J., and Sausville E.A. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 63 (2003) 766-772
19. Newman D., Sakaue M., Koo J.S., Kim K.S., Baek S.J., Eling T., and Jetten A.M. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 63 (2003) 557-564
20. Lee S.H., Yamaguchi K., Kim J.S., Eling T.E., Safe S., Park Y., and Baek S.J. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27 (2006) 972-981
21. Kim K.S., Baek S.J., Flake G.P., Loftin C.D., Calvo B.F., and Eling T.E. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 122 (2002) 1388-1398
22. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., Austin R.C., and Klamut H.J. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275 (2000) 20127-20135
23. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67 (2005) 356-364
24. Yamaguchi K., Lee S.H., Eling T.E., and Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3β pathway. J Biol Chem 279 (2004) 49617-49623
25. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
26. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., and Bos J.L. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
27. Kinzler K.W., Nilbert M.C., Vogelstein B., Bryan T.M., Levy D.B., Smith K.J., Preisinger A.C., Hamilton S.R., Hedge P., Markham A., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251 (1991) 1366-1370
28. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
29. Kishimoto Y., Morisawa T., Hosoda A., Shiota G., Kawasaki H., and Hasegawa J. Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane. J Exp Clin Cancer Res 21 (2002) 203-211
30. Papanikolaou A., Wang Q.S., Papanikolaou D., Whiteley H.E., and Rosenberg D.W. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21 (2000) 1567-1572
31. Takahashi M., Mutoh M., Kawamori T., Sugimura T., and Wakabayashi K. Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21 (2000) 1319-1327
32. Ward J.M., Yamamoto R.S., and Brown C.A. Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane. J Natl Cancer Inst 51 (1973) 1029-1039
33. Povey A.C., Badawi A.F., Cooper D.P., Hall C.N., Harrison K.L., Jackson P.E., Lees N.P., O'Connor P.J., and Margison G.P. DNA alkylation and repair in the large bowel: animal and human studies. J Nutr 132 (2002) 3518S-3521S
34. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59 (2001) 901-908
35. Araki K., Araki M., Miyazaki J., and Vassalli P. Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc Natl Acad Sci U S A 92 (1995) 160-164
36. O'Gorman S., Dagenais N.A., Qian M., and Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc Natl Acad Sci U S A 94 (1997) 14602-14607
37. Boivin G.P., Washington K., Yang K., Ward J.M., Pretlow T.P., Russell R., Besselsen D.G., Godfrey V.L., Doetschman T., Dove W.F., Pitot H.C., Halberg R.B., Itzkowitz S.H., Groden J., and Coffey R.J. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124 (2003) 762-777
38. Su L.K., Kinzler K.W., Vogelstein B., Preisinger A.C., Moser A.R., Luongo C., Gould K.A., and Dove W.F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256 (1992) 668-670
39. Chiu C.H., McEntee M.F., and Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 57 (1997) 4267-4273
40. Toraldo G., Roggia C., Qian W.P., Pacifici R., and Weitzmann M.N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor-κB ligand and tumor necrosis factor α from T cells. Proc Natl Acad Sci U S A 100 (2003) 125-130
41. Bauskin A.R., Zhang H.P., Fairlie W.D., He X.Y., Russell P.K., Moore A.G., Brown D.A., Stanley K.K., and Breit S.N. The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-β superfamily member, acts as a quality control determinant for correctly folded MIC-1. EMBO J 19 (2000) 2212-2220
42. Robles A.I., Bemmels N.A., Foraker A.B., and Harris C.C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61 (2001) 6660-6664
43. Kannan K., Amariglio N., Rechavi G., Jakob-Hirsch J., Kela I., Kaminski N., Getz G., Domany E., and Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20 (2001) 2225-2234
44. Lee D.H., Yang Y., Lee S.J., Kim K.Y., Koo T.H., Shin S.M., Song K.S., Lee Y.H., Kim Y.J., Lee J.J., Choi I., and Lee J.H. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63 (2003) 4648-4655
45. Karan D., Chen S.J., Johansson S.L., Singh A.P., Paralkar V.M., Lin M.F., and Batra S.K. Dysregulated expression of MIC-1/PDF in human prostate tumor cells. Biochem Biophys Res Commun 305 (2003) 598-604
46. Brown D.A., Bauskin A.R., Fairlie W.D., Smith M.D., Liu T., Xu N., and Breit S.N. Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 33 (2002) 118-124
47. Lindmark F., Zheng S.L., Wiklund F., Bensen J., Balter K.A., Chang B., Hedelin M., Clark J., Stattin P., Meyers D.A., Adami H.O., Isaacs W., Gronberg H., and Xu J. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 96 (2004) 1248-1254
48. Jennrich R.I., and Schluchter M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 42 (1986) 805-820
49. Conover W. Practical nonparametric statistics (1971), John Wiley & Sons, Inc, Hoboken, NJ